Comparison of hematologic and cytogenetic response rates by deletion status and disease phase
Further phase/response . | Patients with deletions, n (%) . | Patients without deletions, n (%) . | P . |
|---|---|---|---|
| CP1, all patients | 44 | 231 | |
| CHR | 33/37 (89) | 178/184 (97) | .04 |
| MCR | 23/42 (55) | 173/231 (75) | .008 |
| CCR | 16/44 (36) | 115/227 (50) | .08 |
| CP1, newly diagnosed | 11 | 40 | |
| CHR | 8/9 (88) | 37/40 (92) | .56* |
| MCR | 8/11 (73) | 35/40 (87) | .23* |
| CCR | 8/11 (73) | 29/38 (76) | .54* |
| CP1, interferon-α failure | 33 | 191 | |
| CHR | 25/28 (89) | 141/144 (98) | .02 |
| MCR | 15/31 (48) | 138/191 (72) | .008 |
| CCR | 8/33 (24) | 86/189 (45) | .02 |
| Advanced phase | 13 | 103 | |
| HR | 6/13 (46) | 85/103 (83) | .007 |
| MCR | 1/12 (8) | 27/98 (27) | .13 |
| CCR | 0/11 | 11/92 (12) | .27 |
Further phase/response . | Patients with deletions, n (%) . | Patients without deletions, n (%) . | P . |
|---|---|---|---|
| CP1, all patients | 44 | 231 | |
| CHR | 33/37 (89) | 178/184 (97) | .04 |
| MCR | 23/42 (55) | 173/231 (75) | .008 |
| CCR | 16/44 (36) | 115/227 (50) | .08 |
| CP1, newly diagnosed | 11 | 40 | |
| CHR | 8/9 (88) | 37/40 (92) | .56* |
| MCR | 8/11 (73) | 35/40 (87) | .23* |
| CCR | 8/11 (73) | 29/38 (76) | .54* |
| CP1, interferon-α failure | 33 | 191 | |
| CHR | 25/28 (89) | 141/144 (98) | .02 |
| MCR | 15/31 (48) | 138/191 (72) | .008 |
| CCR | 8/33 (24) | 86/189 (45) | .02 |
| Advanced phase | 13 | 103 | |
| HR | 6/13 (46) | 85/103 (83) | .007 |
| MCR | 1/12 (8) | 27/98 (27) | .13 |
| CCR | 0/11 | 11/92 (12) | .27 |
The rates of CHR, MCR, and CCR achieved in patients according to deletion status and disease phase are shown when available. These rates are compared for deletion status by the χ2 test with the P values shown.
P determined by Fisher exact test.